RxDoctor Payments Data

Ricardo Fernandez, MD

Internal Medicine · Upper Marlboro, MDNPI 1609913532

Payments from drug & device makers

$34,840in general payments, 2019–2025

Across 54 payments — averaging $645.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$34K
  • Viiv Healthcare Company$233
  • Exact Sciences$62
  • Gilead$60
  • Johnson & Johnson$53
  • Sanofi Pasteur Inc.$53
  • plus $262 from 7 others

What the payments were for

  • Speaking & faculty fees$32,97495%
  • Travel & lodging$2871%
  • Food & beverage$1,5334%
  • Education$450%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,840 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$10,556
Medicare patients
50
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala27$112,622
GenvoyaElviteg/Cob/Emtri/Tenof Alafen23$91,998
TriumeqAbacavir/Dolutegravir/Lamivudi11$43,343
OzempicSemaglutide33$32,523
DescovyEmtricitabine/Tenofov Alafenam13$29,342
RybelsusSemaglutide18$25,967
JardianceEmpagliflozin21$24,406
TrulicityDulaglutide13$17,574
JanuviaSitagliptin Phosphate11$13,173
Advair HfaFluticasone Propion/Salmeterol18$5,186
SymbicortBudesonide/Formoterol Fumarate13$3,005
Diclofenac Sodium42$1,549
Gabapentin18$1,060
Atorvastatin Calcium115$652
Chlorthalidone37$557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$60$233,96263 claims
Viiv Healthcare CompanyTriumeq$233$43,34311 claims
MerckJanuvia$53$13,17311 claims
AstraZenecaSymbicort$23$3,00513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Upper Marlboro

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →